Key Factors That Could Impact Eli Lilly’s Stock Price
Drug Pipeline and Clinical Development Successes: FDA approval of donanemab (Alzheimer’s) or oral GLP-1 therapies (e.g., orforglipron) could drive growth. Breakthroughs in oncology or …